<DOC>
	<DOCNO>NCT02958800</DOCNO>
	<brief_summary>Aggressive behaviour long-term care ( LTC ) difficult health care issue manage . One method over-used prescription antipsychotic behaviours psychological symptom dementia ( BPSD ) . This high prevalence use recognize health care problem Ontario around world ; increase antipsychotic use associate increased fall mortality . Existing strategy educational nature systematic ; goal study develop systematic algorithm help LTC physicians deprescribe taper antipsychotic safely effectively . The objective study : 1 ) Develop discontinuation algorithm antipsychotic base single patient open-label ( SPOT ) trial methodology ( e.g . variation N-of-1 trial ) standardize outcome measure LTC physician ; 2 ) To pilot clinical pharmacist-led recruitment strategy ; 3 ) To provide preliminary evidence demonstrate algorithm could lead deprescribing anti-psychotic medication LTC .</brief_summary>
	<brief_title>Deprescribing Antipsychotics Long-Term Care</brief_title>
	<detailed_description>This pilot study consist enrol long-term care ( LTC ) patient 12-week , single-patient , open-label , randomized multiple crossover trial consist 2 different treatment block ( Block A , Block B ) 3 week duration . This study target LTC resident two Hamilton LTC facility associate MediSystem pharmacy . Once potential participant identify clinical pharmacist work two facility , invitation letter consent letter send LTC resident 's power attorney health care ( POA-HC ) describe study invite complete mail back consent form . POA-HCs provide contact information research assistant associate study order question answer . Once consent receive , LTC patient assign randomized 1:1 treatment sequence Block A ( denote `` A '' ) Block B ( denote `` B '' ) . For example , Patient1 may assign treatment sequence AABB , Patient2 may assign treatment sequence BAAB , . The patient take pre-determined dose , DOSE-A , antipsychotic agree upon physician POA-HC time enrolment Block A . This pre-determined dose less current dose LTC patient take time enrolment . Similarly , LTC patient take DOSE-B , second pre-determined dose antipsychotic different start dose DOSE-A , take Block B . At end 12-week study , LTC physicians give report describe summarize outcome measure participate LTC patient . This report review together POA-HC order make clinical decision together whether continue use antipsychotic medication , whether decrease discontinue dose appropriate . After decision , six-month prospective chart review do determine whether clinical decision result 12-week study persist . If subsequent change occur six-month prospective time period , reason rationale change record .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>LTC resident stable antipsychotic dose &gt; 3 month ( i.e . change dose make time frame ) Most recent RAIMDS ( Resident Assessment Instrument Minimum Data Set ) 2.0 quarterly assessment document change tracked behaviour past 3 month current antipsychotic dos Power Attorney Healthcare ( POAHC ) locally present able consent POAHC proficient communicate fluently English Chart indication use antipsychotic manage psychiatric condition ( e.g . schizophrenia , bipolar disorder , active hallucination delusion ) Currently prescribe routine oral risperidone , olanzapine quetiapine Chart indication use antipsychotic psychosis relate mental health diagnosis POAHC locally present communicate fluently English</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Deprescribing</keyword>
	<keyword>Single patient open label trial</keyword>
	<keyword>Long-term care</keyword>
</DOC>